Results 11 to 20 of about 1,588,451 (244)

Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy

open access: yesCancer Management and Research, 2017
Lingdong Shao,* Qingqin Peng,* Kaixin Du,* Junyan He, Yaping Dong, Xiaoyi Lin, Jinluan Li, Junxin Wu Department of Radiation Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, People’s Republic of China *These ...
Shao LD   +7 more
doaj   +1 more source

PD-1/PD-L1 blockade accelerates the progression of atherosclerosis in cancer patients

open access: yes, 2022
PD-1(programed death-1)/PD-L1(programed death-1 ligand) blockade represents a major breakthrough of anti-cancer therapies, however, it may come with increased risk of cardiovascular morbidity, such as myocarditis, acute coronary syndrome, arrhythmias ...
Tse, Gary   +8 more
core   +2 more sources

PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect

open access: yes, 2022
Immune checkpoint blockers (ICBs) targeting programmed death receptor 1 (PD-1) ligand 1 (PD-L1) for immunotherapy have radically reformed oncology. It is of great significance to enhance the response rate of ICB in cancer patients. Here, a radioiodinated
Yiren Zhang (1760983)   +11 more
core   +1 more source

PD-L1-Expressing Extracellular Vesicles for the Treatment of Pneumonia

open access: yes, 2023
Acute respiratory distress syndrome (ARDS) is a severe lung condition with a high mortality rate and a lack of effective drug therapy. In this work, we developed mesenchymal stem cell (MSC)-derived extracellular vesicles with high PD-L1 expression (MSC ...
Ting Lu (149031)   +10 more
core   +1 more source

Identification of a Small Molecule that Binds to the PD-L1 Dimer Interface [PDF]

open access: yes, 2023
In recent years, antibody drugs targeting PD-1/PD-L1 immune checkpoints have shown immense clinical benefits in cancer treatment. However, these drugs suffer from poor patient tolerance, large and difficult-to-control adverse reactions, insufficient oral
Hengwei, Bian   +11 more
core   +1 more source

Image_1_Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance.tif

open access: yes, 2022
The contribution of natural killer (NK) cells to tumor rejection in the context of programmed death-ligand 1/programmed death 1 (PD-L1/PD-1) blockade is a matter of intense debate.
Maria-Luisa del Rio (12894632)   +5 more
core   +1 more source

PD-L1: expression regulation

open access: yesBlood Science, 2023
Programmed death-ligand 1 (PD-L1), expressed on the surface of tumor cells, can bind to programmed cell death-1 (PD-1) on T cells. The interaction of PD-1 and PD-L1 can inhibit T-cell responses by decreasing T-cell activity and accelerating their ...
Yu-Jie Zhou   +7 more
doaj   +1 more source

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression [PDF]

open access: yes, 2023
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related morbidity and mortality worldwide. Immune checkpoint inhibitors (ICIs) including anti-PD-1 and anti-PD-L1 antibodies, have significantly changed the treatment outcomes with better ...
Raza, Afsheen   +45 more
core   +1 more source

Supporting data for "Immunophenotyping of anti-PD-L1-treated hepatocellular carcinoma"

open access: yes, 2023
Hepatocellular carcinoma (HCC) is a deadly disease. The FDA recently approved the first immunotherapy, atezolizumab (anti-PD-L1) plus bevacizumab (anti-VEGF-A), for advanced HCC. Nonetheless, there are still patients not responding.
Fu Wan Sit (11211570)
core   +1 more source

Establishment of Human PD-1/PD-L1 Blockade Assay Based on Surface Plasmon Resonance (SPR) Biosensor

open access: yesBio-Protocol, 2023
Blockade of the programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) axis is a promising strategy for cancer immunotherapy. Although antibody-based PD-1/PD-L1 inhibitors have shown remarkable results in clinical cancer studies, their inherent ...
Tess Puopolo   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy